Aspirin for the Primary Prevention of Cardiovascular Disease in Women

被引:1
|
作者
Bailey A.L. [1 ]
Campbell C.L. [2 ]
Smyth S.S. [3 ]
机构
[1] Gill Heart Institute and the Division of Cardiovascular Medicine, The University of Kentucky, Lexington, KY, 40536, 900 South Limestone
[2] Gill Heart Institute and the Division of Cardiovascular Medicine, Lexington Veteran's Administration Medical Center, The University of Kentucky, Lexington, KY, 40536, 900 South Limestone
[3] Gill Heart Institute and the Division of Cardiovascular Medicine, Lexington Veteran's Administration Medical Center, The University of Kentucky, Lexington, KY, 40536
关键词
Aspririn; Primary prevention of cardiovascular disease; Women's cardiovascular health;
D O I
10.1007/s12170-010-0097-5
中图分类号
学科分类号
摘要
Primary prevention of cardiovascular disease, which is the leading cause of death of women in the United States, focuses on treating or eliminating risk factors and often includes the use of aspirin to prevent thrombotic complications of atherosclerosis or atrial fibrillation. Recent evidence reveals sex-based differences in the benefits of aspirin in individuals without established cardiovascular disease. Although use of aspirin does not affect total mortality in either sex, aspirin lowers the risk of ischemic stroke in women and decreases the risk of myocardial infarction in men. Unfortunately, the use of aspirin comes at the expense of an increase in bleeding events, mostly gastrointestinal, that occurs at roughly similar rates in women and men. Aspirin may not be beneficial for primary prevention of cardiovascular events in women with diabetes. The benefits, as well as the risks, of aspirin therapy should be discussed when contemplating the use of aspirin in the primary prevention of cardiovascular disease in women. © 2010 Springer Science+Business Media, LLC.
引用
收藏
页码:209 / 215
页数:6
相关论文
共 50 条
  • [1] Aspirin for primary prevention of cardiovascular disease in women
    Shufelt, Chrisandra L.
    Manson, JoAnn E.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2020, 27 (05): : 605 - 606
  • [2] Aspirin for primary prevention of cardiovascular disease in women
    Lau, Emily S.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2023, 30 (02): : 215 - 217
  • [3] Aspirin for the Primary Prevention of Atherosclerotic Cardiovascular Disease in Women
    Shufelt, Chrisandra L.
    Mora, Samia
    Manson, JoAnn E.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (07): : 672 - 673
  • [4] Aspirin in the primary prevention of cardiovascular disease
    Galloway, Colin F.
    Stevenson, John C.
    MATURITAS, 2011, 68 (01) : 3 - 4
  • [5] Aspirin for primary prevention of cardiovascular disease
    Nansseu J.R.N.
    Noubiap J.J.N.
    Thrombosis Journal, 13 (1)
  • [6] Aspirin for primary prevention of cardiovascular disease
    Waltering, A
    Hemkens, L
    Florack, C
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2005, 130 (49) : 2847 - 2852
  • [7] Aspirin for primary prevention of cardiovascular disease
    Gelbenegger, G.
    Postula, M.
    Pecen, L.
    Halvorsen, S.
    Lesiak, M.
    Schoergenhofer, C.
    Jilma, B.
    Hengstenberg, C.
    Siller-Matula, J. M.
    EUROPEAN HEART JOURNAL, 2019, 40 : 276 - 276
  • [8] Aspirin for primary prevention of cardiovascular disease
    Capodanno, Davide
    Angiolillo, Dominick J.
    LANCET, 2018, 392 (10152): : 988 - 990
  • [9] Aspirin for primary prevention of cardiovascular disease
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2000, 42 (1072): : 18 - 18
  • [10] Aspirin in the prevention of cardiovascular disease in women
    Schwartz, DJ
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (26): : 2751 - 2751